Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 43Lymphoma, Follicular 23Lymphoma, Non-Hodgkin 17Lymphoma, Mantle-Cell 16Lymphoma, Large B-Cell, Diffuse 15Lymphoma 14Lymphoma, B-Cell, Marginal Zone 12Lymphoma, B-Cell 8Recurrence 7Neoplasms 6Burkitt Lymphoma 5Leukemia, B-Cell 4Neoplasm, Residual 3Leukemia, Hairy Cell 2Leukemia 2Dendritic Cell Sarcoma, Interdigitating 2Waldenstrom Macroglobulinemia 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Part1: Advanced B-cell Malignancies 1Ovarian Neoplasms 1Mesothelioma 1Melanoma 1Mature B-cell Malignancies 1Mature B-Cell Malignancies 1Lymphoproliferative Disorders 1Lymphatic Diseases 1Leukemia, Prolymphocytic 1

Interventions

Cyclophosphamide 5fludarabine 4fludarabine phosphate 3acalabrutinib 2Whole-Body Irradiation 2Tacrolimus 2Rituximab 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Melphalan 2Busulfan 2Bendamustine Hydrochloride 2pembrolizumab 1obinutuzumab 1ibrutinib 1Vincristine 1Prednisone 1Doxorubicin 1CA-4948 1Bone Marrow Transplantation 1ARQ531 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphatic Diseases × obinutuzumab × 1 year × Clear all
NCT06651970 2026-05-18

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

AstraZeneca

Phase 4 Recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Heart Failure, Lymphatic Diseases, Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡